Related Experiment Video
Updated: Jul 5, 2025
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
Published on: February 14, 2022
Heart Transplantation
Nikolaos Chrysakis1, Dimitrios E Magouliotis2, Kyriakos Spiliopoulos2
1Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece.
Insights
Heart transplantation (HTx) is a critical treatment for advanced heart failure. Recent advancements in donor selection, rejection monitoring, and immunosuppression therapies are improving outcomes for this life-saving procedure.
Area of Science:
- Cardiology
- Transplantation Medicine
- Immunology
Background:
- Heart transplantation (HTx) is the final treatment option for end-stage heart failure.
- Patient outcomes are influenced by factors including compatibility, graft quality, and post-operative care.
- Organ allocation policies have been revised to prioritize critically ill patients.
Purpose of the Study:
- To review current challenges and recent advancements in heart transplantation.
- To discuss factors affecting HTx outcomes and contraindications.
- To highlight novel therapies and techniques in the field.
Main Methods:
- Clinically focused review of existing literature and data.
- Analysis of factors influencing heart transplant success.
- Discussion of recent technological and therapeutic innovations.
Main Results:
- Key factors influencing HTx outcomes include ABO/HLA compatibility, graft size, ischemic time, patient age, and infections.
- Updated UNOS policy aims to reduce waiting list mortality by prioritizing sicker patients.
- Major complications include rejection, infection, neoplasms, and graft failure.
Conclusions:
- Despite challenges, heart transplantation remains vital for advanced heart failure.
- Recent innovations like xenotransplantation and new immunosuppressants show promise.
- Ongoing research focuses on improving donor selection, monitoring, and treatment strategies.
Abstract:
Heart transplantation (HTx) remains the last therapeutic resort for patients with advanced heart failure. The present work is a clinically focused review discussing current issues in heart transplantation. Several factors have been associated with the outcome of HTx, such as ABO and HLA compatibility, graft size, ischemic time, age, infections, and the cause of death, as well as imaging and laboratory tests. In 2018, UNOS changed the organ allocation policy for HTx. The aim of this change was to prioritize patients with a more severe clinical condition resulting in a reduction in mortality of people on the waiting list. Advanced heart failure and resistant angina are among the main indications of HTx, whereas active infection, peripheral vascular disease, malignancies, and increased body mass index (BMI) are important contraindications. The main complications of HTx include graft rejection, graft angiopathy, primary graft failure, infection, neoplasms, and retransplantation. Recent advances in the field of HTx include the first two porcine-to-human xenotransplantations, the inclusion of hepatitis C donors, donation after circulatory death, novel monitoring for acute cellular rejection and antibody-mediated rejection, and advances in donor heart preservation and transportation. Lastly, novel immunosuppression therapies such as daratumumab, belatacept, IL 6 directed therapy, and IgG endopeptidase have shown promising results.
